[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611077":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":25,"responsibleParty":56,"collaborators":18,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":18,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":18,"enrollmentInfo":68,"targetDuration":18,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":81,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Alexandria University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention arm (Finerenone)","EXPERIMENTAL","Treatment arm: will receive oral Finerenone in addition to standard treatment.\n\nInitial dose of finerenone will be determined according to eGFR:\n\neGFR\\>= 60 mL\u002Fmin: 20 mg once daily. eGFR\\>25 mL\u002Fmin, \\\u003C60 mL\u002Fmin: 10 mg once daily eGFR\\\u003C15 mL\u002Fmin: use is contraindicated Maintenance dose will be determined by the serum potassium level measured 4 weeks after initiation of therapy or dose adjustment according to CKD progression",[13],"Drug: Finerenone",{"label":15,"type":16,"description":17,"interventionNames":18},"Control arm","NO_INTERVENTION","Control arm: will receive standard treatment according to patient's condition and symptoms.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Finerenone","Finerenone, a novel orally administered selective non-steroidal MRA demonstrates stronger affinity to the mineralocorticoid receptor (MR) in comparison with eplerenone and spironolactone resulting in better efficacy in aldosterone's inhibition.",[9],[26],{"facility":5,"status":18,"city":27,"state":18,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Alexandria","21532","Egypt","EG",{"type":32,"coordinates":33},"Point",[34,35],29.91582,31.20176,{"lat":35,"lon":34},[38,43,46,48,50,52,54],{"name":39,"role":40,"phone":41,"phoneExt":18,"email":42},"Merna M. AbouKhatwa","CONTACT","+201115966255","merna.abokhatwa@alexu.edu.eg",{"name":44,"role":45,"phone":18,"phoneExt":18,"email":18},"Labiba K. El-Khordagui, Prof.","PRINCIPAL_INVESTIGATOR",{"name":47,"role":45,"phone":18,"phoneExt":18,"email":18},"Ahmed A. El-Masry, Prof.",{"name":49,"role":45,"phone":18,"phoneExt":18,"email":18},"Ahmed F. El-Keraie, Prof.",{"name":51,"role":45,"phone":18,"phoneExt":18,"email":18},"Ahmed F. El-Yazbi, Prof.",{"name":53,"role":45,"phone":18,"phoneExt":18,"email":18},"Noha A. Hamdy, Assoc. Prof.",{"name":55,"role":45,"phone":18,"phoneExt":18,"email":18},"Merna M. AbouKhatwa, Assistant Lecturer",{"type":45,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Merna Abou Khatwa","Assistant Lecturer","100611077","phase-4-retinal-protective-effects-of-novel-finerenone-in-patients-with-chronic-kidney-disease-100611077",false,"NCT07235891","Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease","Investigating the Impact of Finerenone on Retinal Vascular Dysfunction in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* Age: above 18 years\n* Diabetic and non-diabetic non-hemodialysis CKD patients (Stage 2 - Stage 4).\n\nExclusion Criteria:\n\n* Patients on hemodialysis (HD).\n* Serum potassium level \\> 5.5 mEq\u002FL\n* Prior\u002Fplanned ocular interventions (retinal laser treatment, intravitreal injection or vitrectomy).\n* Pregnant and lactating women\n* Malignancy","ALL","18 Years",{"count":69,"type":70},40,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","Interestingly, A hypothesis-generating analysis was conducted from two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR\u002FDeFineDR), suggesting a potential benefit of finerenone in the delay of progression of non-proliferative diabetic retinopathy (NPDR), independent of baseline HbA1c. Potential benefits of finerenone were also observed in the prevention of required ocular interventions. However, the studies relied on routine ophthalmological examinations done retrospectively, which may have affected data quality and certainly affected quantity. Hence, there is a compelling need to conduct randomized studies with adequate power to detect a potential benefit of finerenone in delaying retinopathy progression, particularly given the lack of alternative options for oral treatment of retinopathy.",[76,77],"Retinal Nerve Fiber Layer Thickness","Chronic Kidney Disease",[79,22,80],"Retinal dysfunction","Chronic kidney disease","NOT_YET_RECRUITING","2025-11-14",{"date":84,"type":85},"2025-11-19","ACTUAL",{"date":87,"type":70},"2025-11-20",{"date":89,"type":70},"2027-03-20",{"name":5,"class":6},1]